These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36980649)

  • 1. CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer.
    Nabieva N; Fasching PA
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis.
    Tong F; Lu Y; Ma HF; Shen J
    Heliyon; 2024 Jun; 10(11):e31583. PubMed ID: 38832268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging CDK4/6 inhibitor for breast cancer treatment.
    Sheikh MS; Satti SA
    Mol Cell Pharmacol; 2021; 13(3):9-12. PubMed ID: 35251463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.
    Byers KF
    J Adv Pract Oncol; 2021; 12(1):100-107. PubMed ID: 33552665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement.
    Nabieva N; Fasching PA
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.
    Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q
    Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
    D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D
    Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.
    O'Sullivan CC
    Int J Cancer Clin Res; 2015; 2(4):. PubMed ID: 26726315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.